# Sources — Lou Gehrig

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 4, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. Ray JL. “Lou Gehrig.” Society for American Baseball Research (SABR) BioProject. Supports his birth as Henry Louis Gehrig on June 19, 1903, in the Yorkville section of Manhattan to Heinrich and Christina Gehrig, German immigrants; the deaths of his sister Anna in September 1902 at about three months, of his sister Sophie in the winter of 1906 of measles, diphtheria and bronchopneumonia, and of an unnamed infant brother; his enrollment at Columbia University on a football scholarship in February 1921; the 1938 season with a lumbago attack, a jammed thumb and a sharp fall in his hitting; his collapse while ice skating in the winter of 1938 to 1939 and while putting on his uniform pants in spring training; the Mayo Clinic diagnosis of ALS after six days of tests, learned on his 36th birthday; Lou Gehrig Appreciation Day on July 4, 1939, before nearly 42,000 fans; his acceptance in October 1939 of Mayor La Guardia’s appointment as a New York City Parole Commissioner, his swearing-in on January 2, 1940, and his quiet resignation about a month before his death; and his death at 10:10 p.m. on June 2, 1941, at home on Delafield Avenue in the Fieldston section of the Bronx. https://sabr.org/bioproj/person/lou-gehrig/
2. National Baseball Hall of Fame and Museum. “Gehrig, Hunter and Frates each furthered cause of ALS cure.” Supports his .295 average in 1938, the first time under .300 since 1925; .143 at the start of 1939 at 35; his taking himself out of the lineup on May 2, 1939, in Detroit after a then-record 2,130 consecutive games; the Mayo Clinic statement that “after a careful and complete examination it was found that he is suffering from amyotrophic lateral sclerosis” and that he “could, however, continue in some executive activity” (the article spells the physician’s name Hobein); his retirement on July 4, 1939, and his speech; and his death at 37 on June 2, 1941. https://baseballhall.org/discover/gehrig-frates-hunter-furthered-als-cause
3. National Baseball Hall of Fame and Museum. “Hall of Fame opened the day of Lou Gehrig’s final game.” Supports that in the spring of 1939 his reflexes had slowed alarmingly, his leaving the lineup on May 2, the consecutive-games record, his July 4 speech, and his death on June 2, 1941. Its “final game” is an exhibition game in Cooperstown on June 12, 1939, which is not used. https://baseballhall.org/discover/gehrig-played-final-game-on-day-hall-of-fame-opened
4. Markel H. “Did Lou Gehrig actually die of Lou Gehrig’s disease?” PBS NewsHour, June 17, 2016. Supports that his first neurological symptoms began in 1938, around his 35th birthday; the Mayo Clinic visit from June 13 to June 19, 1939, and the certification of the diagnosis on June 19 by his internist, Harold Habein; his repeated head injuries, including concussions; the Boston University researchers’ suggestion that repetitive head trauma can cause a syndrome that mimics ALS; and that the Mayo Clinic has sealed his records. It gives May 1, 1939, for his leaving the lineup and June 3, 1941, for his death. https://www.pbs.org/newshour/health/did-lou-gehrig-actually-die-of-lou-gehrigs-disease
5. HISTMED Master Roster v3. Internal project source; its entries were not treated as independent corroboration.

## Clinical guidance

1. Miller RG, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies. *Neurology* 2009 (PMID 19822872). Riluzole to slow progression; gastrostomy to stabilize weight, ideally while FVC is above 50%; noninvasive ventilation for respiratory insufficiency; respiratory measures at regular intervals. https://pubmed.ncbi.nlm.nih.gov/19822872/
2. Miller RG, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment. *Neurology* 2009 (PMID 19822873). Multidisciplinary clinic care; symptom management (cramps, sialorrhea, pseudobulbar affect, spasticity, depression); screening for cognitive and behavioral impairment. https://pubmed.ncbi.nlm.nih.gov/19822873/
3. Shefner JM, et al. A proposal for new diagnostic criteria for ALS (Gold Coast criteria). *Clinical Neurophysiology* 2020 (PMID 32387049). https://pubmed.ncbi.nlm.nih.gov/32387049/
4. Brooks BR, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2000 (PMID 11464847). https://pubmed.ncbi.nlm.nih.gov/11464847/
5. Roggenbuck J, et al. Evidence-based consensus guidelines for ALS genetic testing and counseling. *Ann Clin Transl Neurol* 2023 (PMID 37691292). Genetic testing offered to every person with ALS, with counseling. https://pubmed.ncbi.nlm.nih.gov/37691292/
6. Miller TM, et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. *N Engl J Med* 2022 (PMID 36129998). Tofersen is relevant only to ALS with an SOD1 variant. https://pubmed.ncbi.nlm.nih.gov/36129998/
7. Cedarbaum JM, et al. The ALSFRS-R. *J Neurol Sci* 1999 (PMID 10540002). https://pubmed.ncbi.nlm.nih.gov/10540002/
8. Martin RL, et al. Lateral Ankle Ligament Sprains Revision 2021. *J Orthop Sports Phys Ther* 2021 (PMID 33789434). https://pubmed.ncbi.nlm.nih.gov/33789434/
9. U.S. Preventive Services Task Force: prediabetes and type 2 diabetes (2021), colorectal cancer (2021), depression (2023), unhealthy alcohol use (2018), HIV (2019), hepatitis C (2020), and the A and B recommendations. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations
10. Centers for Disease Control and Prevention. Adult Immunization Schedule by Medical Condition and Other Indication. https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-medical-condition.html
11. Medicare Preventive Services reference (Aether Forge, 2026). https://patrickrutledge.github.io/preventative_services/

The CMID (Aether Forge) has no monograph for ALS, so it is not cited. The assignment describes the 2009 AAN parameters as reaffirmed; the fetched records confirm the two 2009 papers but not a reaffirmation date, so none is claimed. Riluzole liver-test monitoring (monthly for 3 months, then every 3 months) follows the drug’s labeling; the label itself was not fetched. Edaravone is mentioned only as an option with modest evidence in a selected group; no trial or label was fetched for it, and no newer agent is used.

## Editorial resolutions

- **Recent-death rule.** He died in 1941, so the rule does not apply. Every historical claim is limited to what the fetched sources state.
- **Name.** The record uses “Lou Gehrig” and “Mr. Gehrig.” The alias “Henry Louis Gehrig” (SABR) appears in no other record. The nickname “The Iron Horse” was not found in a fetched source and is not used.
- **Index age and dates.** The synthetic date of birth is June 19, 1990 (shift 87 years). The index visit on May 4, 2026 maps to May 4, 1939, two days after he took himself out of the lineup in Detroit (CLM-0004), when he was 35, about a year after his first symptoms (CLM-0011). The visits on May 18, June 29, August 24 and October 19, 2026, the sick visit on July 20, 2026, and the preventive visit on September 21, 2026 map to the same days of 1939; none falls on his Mayo Clinic stay of June 13 to 19 or on July 4, 1939, and all fall well within his lifetime. The modern diagnosis is made on May 18, about a month earlier than the documented diagnosis on June 19, 1939; the timing, EMG findings, test results, scores and treatment are synthetic. He is 36 at the preventive visit, so it is a periodic adult preventive visit (preventive_adult).
- **Presenting problem.** Progressive weakness and loss of coordination (M62.81) is the presenting problem at intake, resolved at the consultation on May 18, 2026, when ALS (G12.21) was diagnosed. It is anchored to the documented decline in 1938 and 1939 (CLM-0004, CLM-0005, CLM-0011). The intake documents state only what was known then: the suspicion of a motor neuron disorder and the mimic work-up. Riluzole, genetic testing, the ALS clinic and the respiratory plan are dated to the consultation; nutrition, speech, mobility and work planning to the visit six weeks later.
- **Death date.** SABR (with the time, 10:10 p.m.) and the Hall of Fame give June 2, 1941; PBS gives June 3. June 2 is used and June 3 is recorded as a conflicting alternative.
- **Head trauma hypothesis.** The PBS essay reports repeated head injuries, including concussions (CLM-0012, D, probable; recorded in the past medical history), and the suggestion that repetitive head trauma can mimic ALS (CLM-0010, R, disputed). The modern episode records a synthetic history of concussions without lasting symptoms, and the consultant states that they do not change the diagnosis or treatment. The sealed Mayo records are noted; no autopsy finding is claimed.
- **Work and the Parole Commission.** His documented acceptance of a Parole Commission appointment in October 1939 (CLM-0008) and the Mayo statement that he could continue in some executive activity (CLM-0006) anchor the modern work-accommodation theme: a desk role in city public service, started two weeks before the last visit, with accommodations. These claims describe events after the true-frame index date and appear only in later documents.
- **Real people.** His parents and siblings appear only in the claims and the family history (D). Harold C. Habein and Mayor La Guardia appear only in documented history. His wife is not named in the claims; his modern wife is unnamed and has no role, and his health care agent is not named. No modern decision, statement or health fact is attributed to any real person. His July 4, 1939 speech is quoted once, as history, from the Hall of Fame.
- **Mood and safety.** PHQ-9 scores stay between 6 and 8 (mild) with no thoughts of self-harm, and PHQ-2 is 1; no behavioral-health diagnosis is coded, so no safety assessment is required. Mood is screened at every visit and psychology is offered, as the AAN parameters advise.
- **Sick visit.** A same-day visit for a left lateral ankle sprain (S93.402A) after tripping on a curb on a day he did not wear his ankle-foot orthosis, chosen because foot drop makes falls an expected risk in ALS, it insinuates no undocumented real diagnosis, and it interacts with the case: the Ottawa rules spare an X-ray, the orthosis plan is reinforced, and the two-month riluzole liver test is drawn. Treated with a brace and a five-day course of ibuprofen.
- **Preventive visit.** A periodic adult preventive visit at age 36 (CPT 99395 and 99497 in plain text): influenza and COVID-19 vaccines (neuromuscular disease raises the risk from respiratory infection), hepatitis B screening with the HepB-CpG series started (second dose at the last visit), a hepatitis C test (negative), HIV already tested at intake, diabetes screening up to date, colorectal screening not yet due, pneumococcal vaccine judged not indicated at his age on the CDC risk-condition list and flagged for review as breathing weakens, and early advance care planning with an unnamed agent.
- **Focused visits.** The four chronic-care follow-ups (the consultation day, six weeks, three months and five months after diagnosis) are documented as focused visits on the AAN ALS practice parameters (2009), the Gold Coast and revised El Escorial criteria, the ALS genetic testing guideline, and riluzole liver monitoring. One protocol deviation is recorded: the one-month ALT on riluzole was missed because no visit fell then; ALT was normal at six weeks (38 U/L), so no harm resulted, and the two- and three-month tests were booked (41 U/L at the sick visit and 35 U/L at three months). Noninvasive ventilation criteria were not met by the last visit (FVC 72% seated and 63% supine, maximal inspiratory pressure -62 cmH2O); overnight oximetry was ordered. The supine FVC and maximal inspiratory pressures are narrative only.
- **Consultation.** The neuromuscular neurology referral and the consultation by Priscilla Nakamura, MD (a fictional consultant), with EMG and nerve conduction studies on the same day, are **S**. The consultant answers the five referral questions in line with what the record shows afterwards: ALS with mimics excluded; the EMG findings and the Gold Coast and revised El Escorial criteria; riluzole (started), genetic testing (no SOD1 variant, so no tofersen), edaravone discussed and deferred by him; the monitoring and intervention thresholds (followed at each visit); and work, mood and planning support (accommodations, psychology, advance care planning).
- **Synthetic content.** All visits, laboratory values, imaging, EMG and nerve conduction findings, genetic results, vital signs, spirometry, ALSFRS-R, PHQ-2, PHQ-9 and AUDIT-C scores, the medicines and doses, his height (183 cm), and his modern household are synthetic. Qualitative results (MRI, EMG and nerve conduction studies, protein electrophoresis, HIV, hepatitis B and C tests, genetic panel, maximal inspiratory pressure, supine FVC) appear only in the note text.
- **Not used.** Mayo Clinic records (sealed), the full Habein letter (the Hall of Fame collection page could not be reached), his wife’s memoir, and accounts of experimental treatments he may have received were not fetched and are not used.
